Business - Briefly   

Merck cancer drug approved by DCGI

NEW DELHI: Merck Specialities on Thursday said it had got the Drugs Controller General of India's (DCGI) approval for its cancer drug, Erbitux.

The drug is prescribed to patients in early stages of neck and head cancer.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Paswan seeks ban on iron ore exports
Kalam wants LIC to go in for paperless policy documents
Patel to take up ATF price issue with oil ministry
Bank stocks to the fore again
Gateway Distriparks to set up freight station
RBI to release Star series notes
Centre to include printing industry under CLCS scheme
SriLankan Airlines into destination marketing
Rupee ends lower
M&M to buy Jeco Holding
SEs to report system hiccups to SEBI
Nalco approves 50 p.c. dividend
GE Finance identifies eight focus areas
Exchange rates
Bullion rates
COAI criticises TRAI on spectrum issue
Merck cancer drug approved by DCGI
Wipro Infrastructure buys Swedish co.
Universal Media fined Rs. 5.75 lakh
NCDEX norms on quantum of trading
Microsoft joins Hughes for broadband ICT kiosks
TPV Tech to launch high end monitors
Network Programs pact with Brooks Automation
Corporation Bank Tiruchi branch shifted
ICRA rating for Karnataka Bank's CDs
Office-bearers of SIMA Cotton Development
Rudra Tech launches anti-virus solution

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu